Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries

BACKGROUND: The recombinant tetravalent live-attenuated dengue vaccine based on the YF 17D vaccine virus backbone (CYD-TDV) demonstrated vaccine efficacy (VE) against symptomatic, virologically confirmed dengue of any serotype from month 13 to month 25 (VCD-DENV-Any(M13→M25)) in the CYD14 (2–14-y-ol...

Full description

Saved in:
Bibliographic Details
Published in:Trans R Soc Trop Med Hyg
Main Authors: Huang, Ying, Moodie, Zoe, Juraska, Michal, Fong, Youyi, Carpp, Lindsay N, Chambonneau, Laurent, Coronel, Diana L, Dayan, Gustavo H, DiazGranados, Carlos A, Gilbert, Peter B
Format: Artigo
Language:Inglês
Published: Oxford University Press 2020
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8245293/
https://ncbi.nlm.nih.gov/pubmed/33369671
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/trstmh/traa154
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items